Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05546658 · ClinicalTrials.gov registry record · Early Phase 1

Effects of Psilocybin in Obsessive Compulsive Disorder

A Early Phase 1 study of Obsessive - Compulsive Disorder, sponsored by Johns Hopkins University.

Recruiting
Registry status
Early Phase 1
Development phase
30
Enrollment target
1
Study location

NCT05546658: Recruiting Early Phase 1 study of Obsessive - Compulsive Disorder, sponsored by Johns Hopkins University.

NCT05546658 is a Early Phase 1 study of Obsessive - Compulsive Disorder that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 30 participants, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05546658, a Early Phase 1 study of Obsessive - Compulsive Disorder, is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
Early Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This study will test the feasibility, safety, and evidence for efficacy of psilocybin administration in participants with obsessive compulsive disorder (OCD). This will serve as a preliminary proof of concept study for future larger studies aimed to investigate the utility, cognitive mechanisms, and neural correlates of this intervention.

Primary Outcome

The 10 Y-BOCS items are each scored on a four-point scale from 0 = "no symptoms" to 4 = "extreme symptoms". The sum of the first five items is a severity index for obsessions, and the sum of the last five an index for compulsions. Total score is used as a measure of severity.

Interventions

  • DRUG Psilocybin

Study Locations (1)

Maryland

  • Johns Hopkins University School of Medicine - Baltimore

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-11-28
Est. Completion 2027-09-12
Phase Early Phase 1
Johns Hopkins University

1,448 total trials

What NCT05546658 shows while recruiting

NCT05546658 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.

NCT05546658 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT05546658 about?

NCT05546658 is a clinical study titled "Effects of Psilocybin in Obsessive Compulsive Disorder". This study will test the feasibility, safety, and evidence for efficacy of psilocybin administration in participants with obsessive compulsive disorder (OCD). This will serve as a preliminary proof of concept study for future larger studies aimed to investigate the utility, cognitive mechanisms, and...

What is the current status of trial NCT05546658?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2022-11-28. Estimated completion is 2027-09-12.

What conditions does trial NCT05546658 study?

This clinical trial studies the following conditions: Obsessive - Compulsive Disorder.

What interventions are being tested in trial NCT05546658?

The interventions under investigation include: Psilocybin (DRUG).

Who is sponsoring clinical trial NCT05546658?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05546658 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obsessive - Compulsive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05546658's enrollment target sits among peer trials

30 57th of 84 higher than 21 of 84 other Obsessive - Compulsive Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obsessive - Compulsive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05546658, the US trial registry maintained by the National Library of Medicine. NCT05546658 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.